valsartan has been researched along with benazepril in 44 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (9.09) | 18.2507 |
| 2000's | 22 (50.00) | 29.6817 |
| 2010's | 15 (34.09) | 24.3611 |
| 2020's | 3 (6.82) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Bellera, CL; Bruno-Blanch, LE; Castro, EA; Duchowicz, PR; Goodarzi, M; Ortiz, EV; Pesce, G; Talevi, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chow, L; De Gasparo, M; Levens, N | 2 |
| Allegrini, P; Baum, HP; Cumin, F; de Gasparo, M; Drexler, H; Kästner, S; Laurent, D; Studer, R; Whitebread, S; Zierhut, W | 1 |
| Arai, Y; Hirose, N; Kawamura, M; Li, J | 1 |
| Aldigier, JC; Botteri, F; Mann, JF; Oddou-Stock, P; Ponticelli, C; Ruilope, LM | 1 |
| Achimastos, AD; Baibas, NM; Kalkana, CB; Mountokalakis, TD; Roussias, LG; Skeva, II; Stergiou, GS | 1 |
| Iwao, H; Izumi, Y; Kawano, H; Kim, S; Kimoto, M; Yoshiyama, M; Zhan, Y | 1 |
| Bedigian, MP; Neutel, JM; Smith, DH; Weir, MR | 1 |
| Cao, H; Ke, YS; Yang, T | 1 |
| Carey, RM; de Gasparo, M; El-Kersh, M; Siragy, HM | 1 |
| Aschwanden, R; Ferber, P; Sadecky, L; Waeber, B | 1 |
| Aros, C; Bertocchi, F; Campbell, R; Fagiani, L; Perna, A; Perticucci, E; Remuzzi, A; Remuzzi, G; Ruggenenti, P; Sangalli, F; Viscarra, C | 1 |
| Andersen, S; Jacobsen, P; Jensen, BR; Parving, HH | 1 |
| Ke, YS; Tao, YY; Yang, H; Yu, GH | 1 |
| Campo, C; Praga, M; Rodicio, JL; Ruilope, LM; Segura, J | 1 |
| Katayama, S; Morita, T; Yagi, S | 1 |
| Han, Z; Liang, X; Wang, H; Xing, Y; Zhou, J | 1 |
| Efstathiou, S; Makris, T; Manolis, A; Papavasiliou, M; Stergiou, GS | 1 |
| Liu, DS; Ye, JF | 1 |
| Jacobsen, PK; Parving, HH; Rossing, P | 1 |
| Berho, M; Elliot, SJ; Plati, AR; Potier, M; Striker, GE; Striker, LJ; Zeng, YJ; Zheng, F | 1 |
| Barker, TA; Berk, BC; Kennedy, AJ; Korshunov, VA; Massett, MP; Mohan, AM | 1 |
| Chen, WD; Huang, YY; Li, LH; Wang, YW; Xu, HH; Yang, LC; Yang, YL; Zhang, DY; Zhu, XJ | 1 |
| Liu, Y; Meng, QH; Wang, L; Zhu, S | 1 |
| Faedda, R; Loriga, G; Ruggenenti, P; Sanna, M; Satta, AE; Vidili, G | 1 |
| Bernheim, A; Brunner-La Rocca, HP; Kiowski, W; Kuster, GM; Morgenthaler, NG; Mueller, B; Nietlispach, F; Rickli, H; Riesen, W; Rüter, F; Schindler, R; Schuetz, P | 1 |
| Battaglia, G; Cambareri, F; Carminati, S; Cravedi, P; David, S; Ene-Iordache, B; Gaspari, F; Granata, A; Ledda, F; Loriga, G; Motterlini, N; Perna, A; Remuzzi, G; Rota, S; Rubis, N; Ruggenenti, P; Satta, A; Stucchi, N; Tonelli, M | 1 |
| Guo, LL; Li, M; Wang, AH | 1 |
| Huang, Y; Jiang, J; Li, Y; Liu, H; Tian, L; Xie, S; Xu, L | 1 |
| Chen, JF; Hung, YJ; Lee, IT; Lee, WJ; Sheu, WH; Wang, CY | 2 |
| Chen, J; Hu, YJ; Peng, DF; Tang, SY | 1 |
| Alpa, M; Cravedi, P; Daina, E; Gamba, S; Gaspari, F; Perna, A; Remuzzi, G; Roccatello, D; Ruggenenti, P | 1 |
| Chen, J; Hu, YJ; Huang, Q; Peng, DF; Peng, X; Tang, SY | 1 |
| Aparicio, MC; Aucella, F; Battaglia, G; Belviso, A; Bossi, AC; Carrara, F; Cortinovis, M; David, S; Diadei, O; Gaspari, F; Gregoric, N; Iliev, IP; Janez, A; Manunta, P; Martinetti, D; P Barlovic, D; Parvanova, A; Peraro, F; Perna, A; Pisani, A; Remuzzi, G; Riccio, E; Rota, S; Ruggenenti, P; Ruggiero, B; Satta, A; Stucchi, N; Trevisan, R; Trillini, M | 1 |
| Habara, M; Haraguchi, T; Ikezaki, H; Kojima, H; Nakamura, S; Uchida, T; Yoshida, M | 1 |
| Chen, J; Jiang, Y; Li, T; Qu, Z; Si, R; Wang, X | 1 |
| Cao, Y; Chen, A; Chen, M; Fan, Y; Guan, X; Li, J; Liu, Y; Yang, D | 1 |
| Aparicio, MC; Belviso, A; Bossi, AC; Carrara, F; Cortinovis, M; De Cosmo, S; Gaspari, F; Iliev, IP; Mangili, R; Martinetti, D; Parvanova, A; Peracchi, T; Perna, A; Prandini, S; Remuzzi, G; Rota, S; Rubis, N; Ruggenenti, P; Tonolo, G; Trevisan, R; Trillini, M | 1 |
1 review(s) available for valsartan and benazepril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
21 trial(s) available for valsartan and benazepril
| Article | Year |
|---|---|
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Creatinine; Drug Combinations; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Middle Aged; Pilot Projects; Potassium; Proteinuria; Safety; Tetrazoles; Valine; Valsartan | 2000 |
Additive hypotensive effect of angiotensin-converting enzyme inhibition and angiotensin-receptor antagonism in essential hypertension.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cross-Over Studies; Diastole; Double-Blind Method; Drug Synergism; Drug Therapy, Combination; Humans; Hypertension; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Systole; Tetrazoles; Time Factors; Valine; Valsartan | 2000 |
Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake.
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Black People; Diuretics; Drug Therapy, Combination; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Pilot Projects; Prospective Studies; Sodium Chloride Symporter Inhibitors; Sodium, Dietary; Tetrazoles; Valine; Valsartan | 2001 |
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Diuretics; Drug Combinations; Drug Resistance; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Middle Aged; Sodium Chloride Symporter Inhibitors; Tetrazoles; Valine; Valsartan | 2001 |
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies.
Topics: Adult; Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Chronic Disease; Cross-Over Studies; Dextrans; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glomerulonephritis, IGA; Humans; Male; Middle Aged; Prospective Studies; Proteinuria; Renal Circulation; Tetrazoles; Valine; Valsartan | 2003 |
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
Topics: Adult; Albuminuria; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cross-Over Studies; Diabetes Mellitus, Type 1; Diabetic Nephropathies; Double-Blind Method; Drug Synergism; Female; Glomerular Filtration Rate; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2003 |
Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardenolides; Digoxin; Female; Humans; Hypertension; Male; Middle Aged; Saponins; Tetrazoles; Valine; Valsartan | 2003 |
Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses.
Topics: Adult; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Drug Therapy, Combination; Female; Humans; Kidney Diseases; Male; Middle Aged; Pilot Projects; Proteinuria; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2003 |
Comparison of antihypertensive effects of an angiotensin-converting enzyme inhibitor, a calcium antagonist and a diuretic in patients with hypertension not controlled by angiotensin receptor blocker monotherapy.
Topics: Adolescent; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure Monitoring, Ambulatory; Calcium Channel Blockers; Chlorthalidone; Cross-Over Studies; Diuretics; Drug Therapy, Combination; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2005 |
[Effects of benazepril combined with valsartan on congestive heart failure].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Drug Therapy, Combination; Female; Heart Failure; Humans; Male; Middle Aged; Tetrazoles; Valine; Valsartan; Ventricular Function, Left | 2005 |
Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Blood Pressure; Circadian Rhythm; Diabetic Nephropathies; Humans; Renin-Angiotensin System; Risk Factors; Tetrazoles; Time Factors; Valine; Valsartan | 2006 |
Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Topics: Administration, Inhalation; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Double-Blind Method; Female; Humans; Hypertension; Kidney; Kidney Diseases; Male; Middle Aged; Prospective Studies; Tetrazoles; Transforming Growth Factor beta1; Valine; Valsartan | 2008 |
Renal hemodynamics and renoprotection.
Topics: Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Female; Humans; Hypertension, Renal; Male; Middle Aged; Proteinuria; Renal Circulation; Renin; Renin-Angiotensin System; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2008 |
Role of RAS inhibition in the regulation of Cu/Zn-SOD in the cardiac and peripheral arterial beds in humans.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Heart Failure; Hemodynamics; Humans; Lipoproteins, LDL; Male; Middle Aged; Oxidative Stress; Renin-Angiotensin System; Superoxide Dismutase; Tetrazoles; Valine; Valsartan | 2010 |
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Chi-Square Distribution; Chronic Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Kidney Diseases; Lipids; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2010 |
[Effects of benazepril and valsartan on erythropoietin levels in patients with essential hypertension].
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Erythropoietin; Female; Hemoglobins; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Pharmacokinetic profiles of hydrochlorothiazide alone and in combination with benazepril or valsartan in healthy Chinese volunteers: evaluation of the potential interaction.
Topics: Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Cross-Over Studies; Diuretics; Drug Interactions; Drug Therapy, Combination; Humans; Hydrochlorothiazide; Male; Middle Aged; Tetrazoles; Valine; Valsartan | 2011 |
Comparison of the efficacy and safety profiles of two fixed-dose combinations of antihypertensive agents, amlodipine/benazepril versus valsartan/hydrochlorothiazide, in patients with type 2 diabetes mellitus and hypertension: a 16-week, multicenter, rando
Topics: Aged; Albuminuria; Amlodipine; Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Benzazepines; Biomarkers; Blood Glucose; Blood Pressure; Calcium Channel Blockers; Diabetes Mellitus, Type 2; Diuretics; Double-Blind Method; Drug Combinations; Female; Glycated Hemoglobin; Humans; Hydrochlorothiazide; Hypertension; Lipids; Male; Middle Aged; Prospective Studies; Taiwan; Tetrazoles; Time Factors; Treatment Outcome; Uric Acid; Valine; Valsartan | 2012 |
Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide.
Topics: Aged; Amlodipine; Antihypertensive Agents; Benzazepines; Brain-Derived Neurotrophic Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; Glomerular Filtration Rate; Humans; Hydrochlorothiazide; Male; Middle Aged; Valsartan | 2015 |
Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial.
Topics: Adult; Aged; Benzazepines; Biomarkers; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Female; Humans; Italy; Kidney Function Tests; Male; Middle Aged; Slovenia; Treatment Outcome; Valsartan | 2019 |
Preventing microalbuminuria with benazepril, valsartan, and benazepril-valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study.
Topics: Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Valsartan | 2021 |
22 other study(ies) available for valsartan and benazepril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
Topics: Humans; Intestinal Absorption; Linear Models; Molecular Conformation; Nonlinear Dynamics; Permeability; Pharmaceutical Preparations; Probability; Quantitative Structure-Activity Relationship; Thermodynamics | 2011 |
Improved glucose metabolism following blockade of angiotensin converting enzyme but not angiotensin AT1 receptors.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Glucose; Blood Pressure; Body Weight; Drug Tolerance; Glucose Intolerance; Hypertension; Insulin Resistance; Lipids; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan | 1995 |
Left ventricular wall stress and sarcoplasmic reticulum Ca(2+)-ATPase gene expression in renal hypertensive rats: dose-dependent effects of ACE inhibition and AT1-receptor blockade.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Benzazepines; Blotting, Northern; Calcium-Transporting ATPases; Dose-Response Relationship, Drug; Heart Ventricles; Hypertension, Renal; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Rats; Rats, Inbred WKY; Sarcoplasmic Reticulum; Tetrazoles; Valine; Valsartan | 1996 |
Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Glucose; Blood Pressure; Body Composition; Glucose Tolerance Test; Insulin; Male; Rats; Rats, Inbred SHR; Tetrazoles; Valine; Valsartan; Weight Gain | 1997 |
Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits.
Topics: Analysis of Variance; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta, Thoracic; Arteriosclerosis; Benzazepines; Cholesterol, Dietary; Disease Models, Animal; Endothelium, Vascular; Immunohistochemistry; Male; Muscle, Smooth, Vascular; Rabbits; Reference Values; Tetrazoles; Valine; Valsartan | 1999 |
Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Catecholamines; Collagen; Diastole; Disease Models, Animal; Drug Therapy, Combination; Echocardiography; Endothelin-1; Gene Expression; Heart Failure; Heart Function Tests; Hydroxyproline; Myocardium; Myosin Heavy Chains; Organ Size; Rats; Rats, Inbred Dahl; Receptors, Angiotensin; RNA, Messenger; Sodium Chloride, Dietary; Survival Rate; Tetrazoles; Valine; Valsartan; Ventricular Remodeling | 2001 |
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Drug Therapy, Combination; Hypertension; Hypertrophy, Left Ventricular; Male; Random Allocation; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrazoles; Valine; Valsartan | 2000 |
Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Bradykinin; Cyclic GMP; Drug Synergism; Extracellular Space; Imidazoles; Kidney; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Sodium; Tetrazoles; Valine; Valsartan | 2001 |
Combined treatment with an AT1 receptor blocker and angiotensin converting enzyme inhibitor has an additive effect on inhibiting neointima formation via improvement of nitric oxide production and suppression of oxidative stress.
Topics: Angioplasty, Balloon; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Carotid Artery Injuries; Disease Models, Animal; Hypertension; Nitric Oxide; Oxidative Stress; Rats; Rats, Sprague-Dawley; Tetrazoles; Tunica Intima; Valine; Valsartan | 2004 |
[Effects of the combined use of benazepril and valsartan on apoptosis in the kidney of rats with adriamycin-induced nephritic glomerulosclerosis].
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Apoptosis; Benzazepines; Doxorubicin; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Glomerulosclerosis, Focal Segmental; Kidney; Male; Membrane Glycoproteins; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Tumor Necrosis Factors; Valine; Valsartan | 2004 |
Combined AGE inhibition and ACEi decreases the progression of established diabetic nephropathy in B6 db/db mice.
Topics: Albuminuria; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Collagen Type IV; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Progression; Drug Therapy, Combination; Enalapril; Female; Glycation End Products, Advanced; Mice; Mice, Inbred C57BL; Mice, Obese; Pyridoxamine; Tetrazoles; Valine; Valsartan; Vitamin B Complex | 2006 |
Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade.
Topics: Amlodipine; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Blood Pressure; Carotid Artery, Common; Cyclic GMP; Male; Rats; Rats, Inbred BN; Receptor, Angiotensin, Type 2; Tetrazoles; Tunica Intima; Tunica Media; Valine; Valsartan | 2006 |
[Effects of benazepril and valsartan alone or in combination on proteinuria in chronic glomerular disease].
Topics: Adolescent; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Chronic Disease; Drug Therapy, Combination; Female; Glomerulonephritis; Humans; Male; Middle Aged; Proteinuria; Tetrazoles; Valine; Valsartan; Young Adult | 2007 |
Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats.
Topics: Angiotensin II; Animals; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Case-Control Studies; Drug Synergism; Heptanoic Acids; Lipids; Male; Natriuretic Peptide, Brain; Proteinuria; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2015 |
A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Cohort Studies; Diltiazem; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Function Tests; Male; Middle Aged; Nephritis, Hereditary; Prospective Studies; Proteinuria; Valsartan | 2015 |
Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS).
Topics: Aged; Antihypertensive Agents; Atorvastatin; Benzazepines; C-Reactive Protein; Cardio-Renal Syndrome; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Protective Agents; Valsartan | 2015 |
A new strategy for taste masking on bitter drug by other combined drug in fixed-dose combination: bitterness of Amlodipine besylate could be masked efficiently by Valsartan.
Topics: Amlodipine; Benzazepines; Captopril; Dose-Response Relationship, Drug; Humans; Hydrochlorothiazide; Taste; Taste Perception; Telmisartan; Valsartan | 2019 |
Increased frequency of PD-1
Topics: Adolescent; Adult; Aged; B-Lymphocytes; Benzazepines; Case-Control Studies; Female; Glomerulonephritis, IGA; Humans; Interleukins; Male; Middle Aged; Prednisone; Programmed Cell Death 1 Receptor; Receptors, CXCR5; Syndecan-1; T-Lymphocytes, Helper-Inducer; Valsartan; Young Adult | 2020 |
Combination of LCZ696 and ACEI further improves heart failure and myocardial fibrosis after acute myocardial infarction in mice.
Topics: Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Benzazepines; Biphenyl Compounds; Disease Models, Animal; Drug Combinations; Drug Therapy, Combination; Fibrosis; Heart Failure; Hemodynamics; Inflammation Mediators; Male; Mice, Inbred C57BL; Myocardial Contraction; Myocardial Infarction; Myocardium; Neprilysin; Protease Inhibitors; Renin; Tetrazoles; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left | 2021 |